Samsung Medical Center
Eine zielgerichtete Therapie in der Republik Korea kostet in der Regel zwischen $5,500 und $11,500. Die endgültigen Kosten hängen vom Medikamententyp, dem Mutationsprofil und der jeweiligen Klinikklasse ab. In Deutschland zahlen Patienten für vergleichbare onkologische Behandlungen im Durchschnitt $6,400. Wer sich für Südkorea entscheidet, kann etwa 14% sparen. Diese Kosten decken meist das Medikament, fachärztliche Beratungen und wichtige diagnostische Kontrolluntersuchungen ab.
Expertentipp von Bookimed: Die Wahl einer Einrichtung wie dem Seoul National University Bundang Hospital (SNUBH) bietet durch den Status als erstes voll digitalisiertes Krankenhaus Koreas einen besonderen Mehrwert. Diese digitale Vernetzung hilft, medizinische Fehler zu minimieren. Wer auf höchstem Niveau versorgt werden möchte, findet im Samsung Medical Center und im Seoul National University Hospital (SNUH) den Goldstandard. Diese Zentren werden von Newsweek regelmäßig als weltweit beste Krankenhäuser ausgezeichnet. Viele erstklassige koreanische Kliniken wie das Severance Hospital und das Korea University Anam Hospital verfügen über eine JCI-Akkreditierung. So gewährleisten sie westliche Sicherheitsstandards bei deutlichen Kostenersparnissen.
Warum wählen Patienten die Republik Korea für zielgerichtete Therapien?
Zugang zu fortschrittlichen Lösungen der zielgerichteten Therapie in vertrauenswürdigen Kliniken .
| Republik Korea | Türkei | Österreich | |
| Gezielte Therapie | von $5,500 | von $1,000 | von $12,000 |
| Lutetium-177-Therapie | von $13,500 | von $8,800 | von $35,000 |
| Onkothermie | - | von $450 | - |
| Aktinium-225-Therapie | - | von $22,955 | von $55,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Gezielte Therapie-Preise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihr Gezielte Therapie bei Ihrer Ankunft.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards für Gezielte Therapie einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu versorgen.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Gezielte Therapie-Reise nie allein.
Tag 1: Ankunft
Tag 2: Voroperationsphase
Tag 3: Gezielte Therapie
Tag 4: Phase nach der Operation
Woche 1-2: Rehabilitation
Bitte beachten Sie, dass der Fall jedes Patienten individuell ist und variieren kann.
Was Patienten mögen:
Was Patienten nicht mögen:
South Korea offers extensive targeted therapy for common cancers like lung, breast, and colorectal but does not cover every type. Availability depends on specific genetic mutations identified through NGS testing. Major institutions like Samsung Medical Center and Severance Hospital provide advanced drugs for cases with approved biomarkers.
Bookimed Expert Insight: While targeted therapy costs start at $5,500, real-world value comes from South Korea’s rapid drug approval cycle. Samsung Medical Center and Seoul National University Hospital often provide access to new therapies years before other regions. This makes Korea a strategic choice for patients seeking the latest FDA-approved molecules that are not yet regional standards.
Patient Consensus: Patients emphasize getting NGS biomarker testing early at major hospitals to unlock treatment options. Many travelers note that while drugs for common mutations are accessible, off-label treatments for rare cases remain expensive without local insurance.
South Korea's top hospitals for targeted therapy include Samsung Medical Center, Severance Hospital, and Seoul National University Hospital. These institutions distinguish themselves through high-volume genomic analysis, Next-Generation Sequencing, and multidisciplinary teams that match specific genetic mutations to precise drug regimens for complex cancers.
Bookimed Expert Insight: Samsung Medical Center and Seoul National University Hospital serve a combined 3.6 million patients annually. This massive volume allows their specialists to encounter rare genetic mutations more frequently than most Western centers. This deep data pool directly improves the accuracy of their Next-Generation Sequencing panels for therapy matching.
Patient Consensus: Patients value the speed of genomic mapping, which often takes only days. Many suggest requesting Next-Generation Sequencing upfront to ensure the most effective therapy match immediately.
South Korean National Health Insurance (NHI) covers many targeted therapies, typically reducing patient costs to 5% of the total medical bill for reimbursed treatments. Coverage depends on specific drug approval for the patient's cancer type and stage as determined by the Health Insurance Review and Assessment Service (HIRA).
Bookimed Expert Insight: While NHI offers significant savings, university hospitals like Severance Hospital or Samsung Medical Center often have higher approval odds for complex cases. These top-tier facilities participate in international clinical trials, providing access to cutting-edge therapies before they reach the official reimbursement list.
Patient Consensus: Patients report that while coverage is generous compared to US costs, the bureaucracy can cause delays. Many recommend bringing detailed genetic reports to speed up the authorization process at major Seoul hospitals.
South Korea accelerates access to targeted drugs through the GIFT (Global Innovative Products on Fast Track) system and the 2025 approval reforms. These pathways prioritize severe or rare diseases. They aim to reduce regulatory review timelines from 420 days to approximately 295 days.
Bookimed Expert Insight: Samsung Medical Center and Severance Hospital often provide the fastest access through named patient programs. These programs allow patients to receive new drugs 3–6 months before official reimbursement. In some cases, these medications are available at 20–50% of the standard US price.
Patient Consensus: Patients report that the prior approval system through major Seoul hospitals can secure insurance coverage for advanced lung cancer drugs like Tagrisso within just a few days.
The Ministry of Food and Drug Safety (MFDS) supervises targeted therapy in the Republic of Korea under the Pharmaceutical Affairs Act. This framework distinguishes between small-molecule drugs and advanced biological products. Specialized systems like the GIFT program and ARMAB Act accelerate access to innovative cancer treatments.
Bookimed Expert Insight: Clinical data from top-tier institutions like Samsung Medical Center and Seoul National University Hospital shows a unique regulatory advantage. These major academic centers often navigate the MFDS approval process for targeted therapies 6 to 12 months faster than the FDA. This speed allows patients to access newer Japanese or European therapies before they reach the US market.
Patient Consensus: Patients emphasize that MFDS approval does not guarantee insurance coverage. Many coordinate with hospital networks to manage out-of-pocket costs for non-reimbursed agents through pharmaceutical assistance programs.